At a glance
- Originator Dainippon Pharmaceutical
- Class Antiulcers; Gastric antisecretories
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Peptic ulcer; Reflux oesophagitis
Most Recent Events
- 20 Jun 2000 Discontinued-Preclinical for Peptic ulcer in Japan (Unknown route)
- 20 Jun 2000 Discontinued-Preclinical for Reflux oesophagitis in Japan (Unknown route)
- 15 Sep 1999 No-Development-Reported for Peptic ulcer in Japan (Unknown route)